Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Cinclus Pharma publishes its Annual Report for 2024

REG

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company developing molecules for the treatment of gastric acid-related diseases, today announced that its Annual Report for 2024 has been published.

The Annual Report is available at https://cincluspharma.com/investors/financial-reports/. The Swedish version of the report is also available in European Single Electronic Format (ESEF).

“The trend is clear. In many of the countries and regions where first-generation PCABs are launched, these are gradually taking over the market from the old proton pump inhibitors (PPIs). Our ambition is to develop a unique next-generation PCAB that meets the medical need and provides the conditions to do exactly what AstraZeneca did when they launched the next-generation PPI, Nexium, twelve years after the introduction of Losec, i.e. to take over the market”, says Christer Ahlberg, CEO, Cinclus Pharma.
 

Datum 2025-04-17, kl 14:00
Källa MFN